Webinar: Register for Cancer Progress Revisited: Making Sense and Cents of IO Combos and their Value

Cancer Progress Revisited: Making Sense and Cents of IO Combos and their Value

Date: Tuesday, June 27, 2017
Time: 12:00 PM – 1:00 PM EDT
9:00 AM – 10:00 AM PDT
5:00 PM – 6:00 PM BST
6:00 PM – 7:00 PM CEST

[ REGISTER ]

On March 7-8th, Defined Health convened its 28th annual Cancer Progress meeting in New York City.  Each year this 2-day event features a unique cross-section of stakeholders (industry, investors, policymakers, nonprofits) in a series of provocative panels that collectively aim to identify and further elucidate many of the issues at the forefront of oncology therapeutics.

With this in mind, please join us on June 27th  for an exciting webinar which, along with our recently released Cancer Progress whitepaper, will revisit some of the key themes that arose throughout the conference and seem to be top of mind for many of us these days such as:

  • Emerging IO modalities & combinations: Which candidates will have impact, and for whom?
  • Perceived value: Who will pay for different regimens, and why?
  • Strategic implications: How to carve out a successful positioning strategy within this context?

 

Presenters:

Joel S. Sandler, PhD, Associate Principal, Defined Health

As an Associate Principal  with Defined Health, Joel provides insight to various life sciences industry clientele (biotechnology/pharmaceutical) on fundamental issues in drug development and partnering based on a comprehensive analysis of the key scientific, clinical, regulatory, and commercial questions relevant to the client’s particular situation. In previous industry roles, Joel was instrumental in the scouting and evaluation of licensing and partnering opportunities for various oncology assets. Prior to his BD&L activities, Joel spent ten years focused on the discovery and characterization of bioactive compounds for cancer and infectious disease research at several leading academic institutions. His work has resulted in numerous grants, fellowships, patent filings, and peer-reviewed publications. He received his BA with honors from Cornell University, a PhD in Organic Chemistry from UCSD, and was a NIH Postdoctoral Fellow at The Rockefeller University.

 


James T. Lee, PhD
, Senior Consultant, Defined Health

James has extensive research, commercial, and strategic perspective on the pharmaceutical and biotech industries. He has a strong expertise in oncology, particularly immuno-oncology, where he has led many client engagements ranging from commercial opportunity assessments to portfolio/platform management. He has helped clients navigate many potential BD&L issues, ranging from in- and out-licensing opportunities and evaluating precommercial biotech clinical development paths.

Before joining Defined Health, James was a Scientist and Oncology Personalized Medicine Project Leader and was involved in numerous preclinical neuroscience and translational oncology projects at Psychogenics. During that time, he managed a diverse collaborative effort to discover and validate drug discovery and preclinical tools for both clients and patients. Previously he completed his postdoctoral fellowship at Columbia University in Oncology in the laboratory of Dr. Wei Gu working with tumor suppressors p53 and PTEN (in collaboration with Dr. Ramon Parsons).

He received a BA from Rutgers University, a PhD in Neuroscience from Emory University, where he studied the molecular mechanisms of Parkinson’s disease.

Roger Longman, CEO, Real Endpoints

Roger Longman is CEO of Real Endpoints, a start-up company focused on pharmaceutical reimbursement, and aiming to help both payers and product developers improve the value of pharmacotherapy.  Its first product assesses – systematically, objectively, and transparently – the value of drugs relative to their competitors.

Until November 2009, Longman was Managing Director, Pharma at Elsevier Business Intelligence, a Reed Elsevier company.  He has been involved with the health-care industry for more than 25 years.

From 1990 through 2008, Longman was co-CEO and managing director of Windhover Information, a company providing analysis and data around pharmaceutical and medical device business strategy through publications, databases and conferences.  Longman co-founded and built the company through internal development (with publications such as IN VIVO, Start-Up and The RPM Report, several databases, including The Strategic Transactions Database; and a series of senior-executive conferences), and through acquisition.

In 2008, Windhover was acquired by Reed Elsevier and merged with its FDC Reports division (publishers of The Pink Sheet, The Gray Sheet and many other medical-industry newsletters), creating Elsevier Business Intelligence.  Longman ran the combined group’s pharmaceutical business until he left in 2010 to begin working on Real Endpoints with Norman Selby, who had been Windhover’s chairman and lead investor.

Over the years, Mr. Longman has become recognized as an expert in biopharmaceutical strategy and often speaks at key industry events organized by important trade organizations, investment banks, venture capital firms and leading pharma and biotech companies. He lectures regularly at several leading universities and co-directed the Wharton-Windhover pharmaceutical program at The Wharton School.  Mr. Longman completed his BA at Cornell University and an MA at the University of North Carolina at Chapel Hill, and then taught for three years at the European division of the University of Maryland.

Kapil Dhingra, MBBS, President, KAPital Consulting

Dr. Dhingra founded KAPital Consulting, LLC, in 2008, a company dedicated to helping biotechnology, pharmaceutical and diagnostic companies realize the clinical and commercial advances in oncology. From 1999 to 2008, Dr. Dhingra served in positions of increasing responsibility at Hoffmann‐La Roche, including Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development.

Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company. From 1989 to 1996, he was a faculty member at The University of Texas M.D. Anderson Cancer Center where he led a successful laboratory as well as clinical research program. Throughout his industry career, Dr. Dhingra maintained an active faculty appointment, at Indiana University School of Medicine from 1997 to 1999, and, more recently, at Memorial Sloan Kettering Cancer Center in New York from 2000 to 2008. Dr. Dhingra holds an MBBS (equivalent to US MD) degree from the All India Institute of Medical Sciences (AIIMS), and has performed postgraduate work at the AIIMS, the Lincoln Medical and Mental Health Center (New York Medical College), Bronx NY and Emory University School of Medicine, Atlanta GA. He is Board‐certified in Internal Medicine and Medical Oncology.

Dr. Dhingra is currently Chairman of Board of Exosome Diagnostics and a member of Board of Directors of Advanced Accelerator Applications (NASDAQ AAAP), Five Prime Inc. (NASDAQ FPRX) and Autolus (UK).  In addition, he is an advisor to several biotechnology and pharmaceutical companies and healthcare organizations. He is also a member of the NCI Experimental Therapeutics panel anda member of the New Drug Advisory Committee of the EORTC. He has previously served on the Boards of several successful biotech companies, including Biovex, Micromet, Algeta, YM Biosciences, and, Epitherapeutics, which were acquired by major pharmaceutical companies.

[ REGISTER ]